Management and Healthcare Utilization of Patients With Chronic Airway Disease During the COVID-19 Epidemic

Asthma Clinical Trial

Official title:

Management and Healthcare Utilization of Patients With COPD and Asthma During the COVID-19 Epidemic in Beijing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04948216
• Other study ID #: LM2020133
• Status: Completed
• Start date: April 28, 2020
• Est. completion date: May 13, 2020

Study information

• Verified date: July 2021
• Source: Peking University Third Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

During the COVID-19 epidemic, the medical treatment, disease status, and medication status of patients with chronic airway disease have not been studied. The purpose of this study is to investigate the management and healthcare utilization of patients with chronic airway disease and the influencing factors during the COVID-19 epidemic.

Description:

During the COVID-19 epidemic, the medical treatment, disease status, and medication status of patients with chronic airway disease have not been studied. The purpose of this study is to investigate the management and healthcare utilization of patients with chronic airway disease and the relevant factors during the COVID-19 epidemic. Using cross-sectional research methods, telephone interviews and questionnaire surveys were used to investigate the management and healthcare utilization of patients with chronic airway disease （COPD and asthma）during the COVID-19 epidemic.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 153
• Est. completion date: May 13, 2020
• Est. primary completion date: May 13, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• COPD patients and asthma patients in the Chronic Airway Disease Database in Peking University Third Hospital.

Exclusion Criteria:

• Refusal to participate in this study; cognitive dysfunction.

Related Conditions & MeSH terms

• Asthma
• Pulmonary Disease, Chronic Obstructive

Intervention

Other:
• No intervention
No intervention

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Respiratory symptoms	COPD Assessment Test (CAT)	through study completion, an average of 2 week.
Primary	Frequency of exacerbation during the COVID-19 epidemic	Frequency of exacerbation during the COVID-19 epidemic	through study completion, an average of 2 week.